CD33 Targeted Therapies
1 drugsAbout CD33
CD33, or Siglec-3, is a transmembrane receptor on myeloid cells like monocytes and granulocytes. It participates in cell-cell interactions and immune regulation as a cell surface marker.
CD33's expression on myeloid lineage cells makes it a therapeutic target, especially in oncology. However, there is currently no genetic evidence directly linking CD33 to specific diseases.
CD33 is targeted by one FDA-approved antibody-drug conjugate, MYLOTARG (gemtuzumab ozogamicin), for acute myeloid leukemia. Pfizer is the sole company with an approved CD33-targeting drug.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Core Binding Factor Acute Myeloid Leukemia with only 1 trials.
- phase3 represents biological uncertainty with 50% completion.
Top CD33 Drugs
Pfizer is the only company with an approved drug targeting CD33.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in the target's validation.
CD33 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CD33, using adc modality.
Explore alternative modalities like bispecifics or CAR-T therapies to differentiate from existing ADCs.
CD33 Clinical Trials 47 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 14 | 8 | 4 | 2 | 67% |
| Phase 2 | 26 | 9 | 4 | 12 | 69% |
| Phase 3 | 6 | 1 | 1 | 4 | 50% |
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
CD33 Drug Approval Timeline (2017 - 2017)
The first and only drug, MYLOTARG, was approved in 2017.
The approval timeline indicates potential saturation; new therapies must demonstrate significant advantages.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 46 clinical trials targeting CD33.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities